Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

1.90

Today's Change

+0.22 (13.09%)

Day's Change

1.67 - 1.96

Trading Volume

3,540,508

Overview

Market Cap

610 Million

Shares Outstanding

321 Million

Avg Volume

2,206,807

Avg Price (50 Days)

2.69

Avg Price (200 Days)

5.21

PE Ratio

-11.87

EPS

-0.16

Earnings Announcement

20-Aug-2025

Previous Close

1.68

Open

1.59

Day's Range

1.675 - 1.96

Year Range

1.43 - 8.975

Trading Volume

3,540,508

Price Change Highlight

1 Day Change

13.10%

5 Day Change

18.75%

1 Month Change

-32.38%

3 Month Change

-51.78%

6 Month Change

-71.98%

Ytd Change

-53.20%

1 Year Change

-29.89%

3 Year Change

252.94%

5 Year Change

26.67%

10 Year Change

26.67%

Max Change

26.67%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment